Get the Stockscreener App
28.10
5.44%
1.5122
Alkermes Plc stock is traded at $28.10, with a volume of 1.31M.
It is up +5.44% in the last 24 hours and down -3.22% over the past month.
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.
See More
Previous Close:
$26.59
Open:
$27.87
24h Volume:
1.31M
Relative Volume:
0.82
Market Cap:
$4.65B
Revenue:
$1.51B
Net Income/Loss:
$333.35M
P/E Ratio:
22.66
EPS:
1.24
Net Cash Flow:
$315.22M
1W Performance:
+6.04%
1M Performance:
-3.22%
6M Performance:
+16.57%
1Y Performance:
+13.09%
1-Day Range:
$27.29
$28.45
1-Week Range:
$25.67
$28.45
52-Week Range:
$22.06
$32.88
Alkermes Plc Stock (ALKS) Company Profile
Name
Alkermes Plc
Sector
Phone
00-353-1-772-8000
Address
CONNAUGHT HOUSE, DUBLIN 4
Alkermes Plc Stock (ALKS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-20-23 | Resumed | JP Morgan | Neutral |
| Oct-24-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Oct-17-23 | Initiated | UBS | Neutral |
| Nov-03-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-14-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Aug-16-22 | Initiated | Piper Sandler | Neutral |
| Apr-22-22 | Resumed | Goldman | Buy |
| Apr-20-22 | Initiated | Goldman | Buy |
| Jan-27-22 | Upgrade | Cantor Fitzgerald | Hold → Overweight |
| Dec-01-21 | Initiated | Citigroup | Neutral |
| Oct-07-21 | Upgrade | Jefferies | Hold → Buy |
| Sep-02-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Oct-15-20 | Upgrade | Mizuho | Neutral → Buy |
| Jul-30-20 | Downgrade | Goldman | Neutral → Sell |
| Feb-14-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Feb-14-20 | Reiterated | H.C. Wainwright | Neutral |
| Feb-14-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Jan-31-20 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Sep-05-19 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Jul-15-19 | Upgrade | Goldman | Sell → Neutral |
| May-31-19 | Initiated | H.C. Wainwright | Neutral |
| May-01-19 | Downgrade | Citigroup | Buy → Neutral |
| Dec-19-18 | Downgrade | Goldman | Neutral → Sell |
| Dec-14-18 | Initiated | Wolfe Research | Underperform |
| Dec-13-18 | Downgrade | Credit Suisse | Outperform → Underperform |
| Nov-05-18 | Initiated | Piper Jaffray | Neutral |
| Aug-07-18 | Initiated | Stifel | Hold |
| Jun-21-18 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jun-06-18 | Initiated | B. Riley FBR, Inc. | Buy |
| May-16-18 | Upgrade | Citigroup | Neutral → Buy |
| May-11-18 | Initiated | BofA/Merrill | Buy |
View All
Alkermes Plc Stock (ALKS) Latest News
Alkermes raised to buy by Stifel on increased confidence for ALKS2680 (NASDAQ:ALKS) - Seeking Alpha
Alkermes (NASDAQ:ALKS) Upgraded by Stifel Nicolaus to Buy Rating - MarketBeat
A Glimpse Into The Expert Outlook On Alkermes Through 9 Analysts - Benzinga
Stifel raises Alkermes target to $36, upgrades to buy - Investing.com India
Stifel raises Alkermes target to $36, upgrades to buy By Investing.com - Investing.com UK
DekaBank Deutsche Girozentrale Lowers Stock Holdings in Alkermes plc (NASDAQ:ALKS) - MarketBeat
(ALKS) Proactive Strategies - Stock Traders Daily
Short Interest in Alkermes plc (NASDAQ:ALKS) Drops By 7.9% - MarketBeat
Alkermes plc (NASDAQ:ALKS) Shares Sold by Allspring Global Investments Holdings LLC - MarketBeat
Alkermes holds steady stock target with neutral rating amid royalty segment dip - Investing.com
Alkermes holds steady stock target with neutral rating amid royalty segment dip By Investing.com - Investing.com South Africa
Alkermes's SWOT analysis: innovative pipeline drives CNS stock's future - Investing.com
Alkermes Eyes Completion of Phase 2 Narcolepsy Studies in 2025 - Sleep Review
Goldman Sachs keeps Alkermes stock buy-rated ahead of milestone readouts, trims PT - Investing.com Canada
Piper Sandler cuts Alkermes stock target, keeps Overweight rating By Investing.com - Investing.com Australia
Leerink maintains Alkermes stock rating with $28 target amid financial projections - Investing.com Australia
Leerink maintains Alkermes stock rating with $28 target amid financial projections By Investing.com - Investing.com South Africa
Alkermes (NASDAQ:ALKS) PT Lowered to $30.00 - MarketBeat
Piper Sandler cuts Alkermes stock target, keeps Overweight rating - Investing.com
Alkermes' Q3 Earnings & Revenues Fall Shy of Estimates, Stock Down - MSN
Alkermes' Q3 Earnings & Revenues Fall Shy Of Estimates, Stock Down - Barchart
Alkermes' (ALKS) Overweight Rating Reiterated at Piper Sandler - MarketBeat
Alkermes plc (NASDAQ:ALKS) Q3 2024 Earnings Call Transcript - Insider Monkey
Earnings call: Alkermes Plc reports solid Q3 growth, eyes future expansion - Investing.com
Alkermes Third Quarter 2024 Earnings: EPS Misses Expectations - Yahoo Finance
Alkermes PLC (ALKS) Q3 2024 Earnings Call Highlights: Strong Pro - GuruFocus.com
Substance Abuse Treatment Market to Witness Massive Growth (2024-2031)| Allergan PLC, Alkermes, Noramco. - openPR
Alkermes PLC (ALKS) Q3 2024 Earnings Call Highlights: Strong Proprietary Product Growth and ... - Yahoo Finance
Alkermes: Q3 Earnings Snapshot - mySA
Alkermes' Q3 Proprietary Sales Soar 18% - The Motley Fool
Alkermes (NASDAQ:ALKS) Shares Gap DownHere's Why - MarketBeat
Moody Aldrich Partners LLC Has $2.38 Million Stock Position in Alkermes plc (NASDAQ:ALKS) - MarketBeat
Alkermes (ALKS) Reports Q3 Earnings: What Key Metrics Have to Say - Yahoo Finance
Alkermes plc Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Fetal Alcohol Spectrum Disorder Treatment Market Overall Study - openPR
Alkermes PLC Q3 2024 Earnings: EPS of $0.56 Beats Estimates, Rev - GuruFocus.com
Alkermes (NASDAQ:ALKS) Updates FY 2024 Earnings Guidance - MarketBeat
Alkermes (ALKS) Lags Q3 Earnings and Revenue Estimates - Yahoo Finance
Alkermes plc Reports Third Quarter 2024 Financial Results - PR Newswire
Alkermes' SWOT analysis: undervalued neuro-innovator stock faces pivotal phase - Investing.com
Alkermes's Earnings: A Preview - Benzinga
Alkermes PLC (ALKS) Q3 2024 Earnings Report Preview: What to Exp - GuruFocus.com
Alkermes (ALKS) Q3 Earnings on the Horizon: Analysts' Insights on Key Performance Measures - Yahoo Finance
Alkermes plc (NASDAQ:ALKS) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Alkermes plc (NASDAQ:ALKS) Stock Holdings Increased by Vontobel Holding Ltd. - MarketBeat
Learn to Evaluate (ALKS) using the Charts - Stock Traders Daily
ALKSAlkermes Inc. plc Latest Stock News & Market Updates - StockTitan
Alkermes (ALKS) to Release Quarterly Earnings on Thursday - MarketBeat
Leerink Partnrs Brokers Cut Earnings Estimates for Alkermes - MarketBeat
Exchange Traded Concepts LLC Cuts Stock Holdings in Alkermes plc (NASDAQ:ALKS) - MarketBeat
Alkermes to Report Third Quarter Financial Results on October 24, 2024 - ShareCast
Alkermes Plc Stock (ALKS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Alkermes Plc Stock (ALKS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Parisi Samuel Joseph | VP, Finance (Interim PAO) |
Feb 27 '24 |
Sale |
29.65 |
2,559 |
75,874 |
7,717 |
| LAURENCIN CATO T | Director |
Feb 15 '24 |
Option Exercise |
22.52 |
2,690 |
60,579 |
17,859 |
| LAURENCIN CATO T | Director |
Feb 15 '24 |
Sale |
31.85 |
2,690 |
85,676 |
15,169 |
1.16%
1.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):